Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis

• Published in: British journal of clinical pharmacology 2019-06, Vol.85 (6), p.1072-1083
• Main Authors: Stone, Julie A., McCrea, Jacqueline B., Witter, Rose, Zajic, Stefan, Stoch, S. Aubrey
• Format: Article
• Language: English
• Subjects: Animals; Biphenyl Compounds - adverse effects; Biphenyl Compounds - pharmacokinetics; Biphenyl Compounds - therapeutic use; Bone and Bones - drug effects; Bone and Bones - enzymology; Bone and Bones - physiopathology; Bone Density Conservation Agents - adverse effects; Bone Density Conservation Agents - pharmacokinetics; Bone Density Conservation Agents - therapeutic use; Bone Remodeling - drug effects; Cathepsin K - antagonists & inhibitors; Cathepsin K - metabolism; clinical trials statistics and study design; Cysteine Proteinase Inhibitors - adverse effects; Cysteine Proteinase Inhibitors - pharmacokinetics; Cysteine Proteinase Inhibitors - therapeutic use; Female; Humans; Male; odanacatib; osteoporosis; Osteoporosis - drug therapy; Osteoporosis - enzymology; Osteoporosis - pathology; pharmacodynamics; pharmacokinetics; Review‐themed Issue; Signal Transduction; Translational Research, Biomedical; Treatment Outcome
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/bcp.13869

Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and localized in the lysosomes and resorption lacunae of these cells. CatK is the principal enzyme responsible for the degradation of bone collagen. Odanacatib is a selective, reversible inhibitor of CatK at subnanomolar potency. The pharmacokinetics of odanacatib have been extensively studied and are similar in young healthy men, postmenopausal women and elderly men, and were qualitatively similar throughout Phase 1 development and in‐patient studies. Following 3 weeks of 50 mg once weekly dosing the geometric mean area under the curve from 0 to 168 hours was 41.1 μM h, the concentration at 168 hours was 126 nM and the harmonic mean apparent terminal half‐life was 84.8 hr. Odanacatib exposure increased in a less than dose proportional manner due to solubility limited absorption. It is estimated that approximately 70% of the absorbed dose of odanacatib is eliminated via metabolism, 20% is excreted as unchanged drug in the bile or faeces, and 10% is excreted as unchanged drug in the urine. The systemic clearance was low (approximately 13 mL/min). Odanacatib decreases the degradation of bone matrix proteins and reduces the efficiency of bone resorption with target engagement confirmed by a robust decrease in serum C‐telopeptides of type 1 collagen (approximately 60%), urinary aminoterminal crosslinked telopeptides of type 1 collagen to creatinine ratio (approximately 50%) and total urine deoxypyridinoline/Cr (approximately 30%), with an increase in serum cross‐linked carboxy‐terminal telopeptide of type 1 collagen (approximately 55%). The 50‐mg weekly dosing regimen evaluated in Phase 3 achieved near maximal reduction in bone resorption throughout the treatment period. The extensive clinical programme for odanacatib, together with more limited clinical experience with other CatK inhibitors (balicatib and ONO‐5334), provides important insights into the clinical pharmacology of CatK inhibition and the potential role of CatK in bone turnover and mineral homeostasis. Key findings include the ability of this mechanism to: (i) provide sustained reductions in resorption markers, increases in bone mineral density, and demonstrated fracture risk reduction; (ii) be associated with relative formation‐sparing effects such that sustained resorption reduction is achieved without accompanying meaningful reductions in bone formation; and (iii) lead to increases in osteoclast number as well as othe